Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

877 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria.
Hillmen P, Muus P, Röth A, Elebute MO, Risitano AM, Schrezenmeier H, Szer J, Browne P, Maciejewski JP, Schubert J, Urbano-Ispizua A, de Castro C, Socié G, Brodsky RA. Hillmen P, et al. Among authors: socie g. Br J Haematol. 2013 Jul;162(1):62-73. doi: 10.1111/bjh.12347. Epub 2013 Apr 25. Br J Haematol. 2013. PMID: 23617322 Free PMC article. Clinical Trial.
Diagnosis and management of paroxysmal nocturnal hemoglobinuria.
Parker C, Omine M, Richards S, Nishimura J, Bessler M, Ware R, Hillmen P, Luzzatto L, Young N, Kinoshita T, Rosse W, Socié G; International PNH Interest Group. Parker C, et al. Among authors: socie g. Blood. 2005 Dec 1;106(12):3699-709. doi: 10.1182/blood-2005-04-1717. Epub 2005 Jul 28. Blood. 2005. PMID: 16051736 Free PMC article. Review. No abstract available.
Paroxysmal nocturnal hemoglobinuria.
Omine M, Kinoshita T, Nakakuma H, Maciejewski JP, Parker CJ, Socié G. Omine M, et al. Among authors: socie g. Int J Hematol. 2005 Dec;82(5):417-21. doi: 10.1532/IJH97.05140. Int J Hematol. 2005. PMID: 16533745 No abstract available.
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P, Röth A, Szer J, Elebute MO, Nakamura R, Browne P, Risitano AM, Hill A, Schrezenmeier H, Fu CL, Maciejewski J, Rollins SA, Mojcik CF, Rother RP, Luzzatto L. Hillmen P, et al. Among authors: socie g. N Engl J Med. 2006 Sep 21;355(12):1233-43. doi: 10.1056/NEJMoa061648. N Engl J Med. 2006. PMID: 16990386 Free article. Clinical Trial.
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria.
Hillmen P, Muus P, Dührsen U, Risitano AM, Schubert J, Luzzatto L, Schrezenmeier H, Szer J, Brodsky RA, Hill A, Socié G, Bessler M, Rollins SA, Bell L, Rother RP, Young NS. Hillmen P, et al. Among authors: socie g. Blood. 2007 Dec 1;110(12):4123-8. doi: 10.1182/blood-2007-06-095646. Epub 2007 Aug 16. Blood. 2007. PMID: 17702897 Free article. Clinical Trial.
Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria.
Schubert J, Hillmen P, Röth A, Young NS, Elebute MO, Szer J, Gianfaldoni G, Socié G, Browne P, Geller R, Rother RP, Muus P; TRIUMPH Study Investigators. Schubert J, et al. Among authors: socie g. Br J Haematol. 2008 Jun;142(2):263-72. doi: 10.1111/j.1365-2141.2008.07183.x. Epub 2008 May 22. Br J Haematol. 2008. PMID: 18503589 Free PMC article. Clinical Trial.
Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine assessment of chimerism post SCT for SAA.
Lawler M, McCann SR, Marsh JC, Ljungman P, Hows J, Vandenberghe E, O'Riordan J, Locasciulli A, Socié G, Kelly A, Schrezenmeier H, Marin P, Tichelli A, Passweg JR, Dickenson A, Ryan J, Bacigalupo A; Severe Aplastic Anaemia Working Party of the European Blood and Marrow Transplant Group. Lawler M, et al. Among authors: socie g. Br J Haematol. 2009 Mar;144(6):933-45. doi: 10.1111/j.1365-2141.2008.07533.x. Epub 2009 Jan 9. Br J Haematol. 2009. PMID: 19183198 Free article.
Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA.
Risitano AM, Selleri C, Serio B, Torelli GF, Kulagin A, Maury S, Halter J, Gupta V, Bacigalupo A, Sociè G, Tichelli A, Schrezenmeier H, Marsh J, Passweg J, Rotoli B; Working Party Severe Aplastic Anaemia (WPSAA) of the European Group for Blood and Marrow Transplantation (EBMT). Risitano AM, et al. Among authors: socie g. Br J Haematol. 2010 Mar;148(5):791-6. doi: 10.1111/j.1365-2141.2009.08027.x. Epub 2009 Dec 7. Br J Haematol. 2010. PMID: 19995389 Free article. Clinical Trial.
Should irradiated blood products be given routinely to all patients with aplastic anaemia undergoing immunosuppressive therapy with antithymocyte globulin (ATG)? A survey from the European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party.
Marsh J, Socie G, Tichelli A, Schrezenmeier H, Hochsmann B, Risitano AM, Fuehrer M, Bekassy AN, Korthof ET, Locasciulli A, Ljungman P, Bacigalupo A, Camitta B, Young NS, Passweg J; European Group for Blood and Marrow Transplantation (EBMT) Severe Aplastic Anaemia Working Party. Marsh J, et al. Among authors: socie g. Br J Haematol. 2010 Aug;150(3):377-9. doi: 10.1111/j.1365-2141.2010.08200.x. Epub 2010 May 26. Br J Haematol. 2010. PMID: 20528874 Free PMC article. No abstract available.
877 results